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DNA repair is an important signaling mechanism that is necessary to maintain genomic stability. Various
types of DNA repair proteins are involved in the repair of different types of DNA damage. However, most
of the DNA repair proteins are modiﬁed post-translation in order to activate their repair function, such as,
ubiquitination, phosphorylation, acetylation, etc. Similarly, DNA repair proteins are also regulated by
posttranscriptional modiﬁcations. Non-coding microRNAs (miRNAs) induced posttranscriptional regu-
lation of mRNAs has gained attention in recent years. MiRNA-induced regulation of DNA repair proteins
is of great interest, owing to its potential role in cancer therapy. In this review, we have summarized the
role of different miRNAs in the regulation of various types of DNA repair proteins, which are essential for
the maintenance of genomic stability.
© 2016 The Author. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).1. Introduction
MicroRNAs (miRNAs) are non-coding RNAs that play an impor-
tant role in various signaling mechanisms in the cells [1]. MiRNAs
are single-stranded and short (usually 21e25 nucleotides) se-
quences that regulate cellular signaling by regulating post-
transcriptional modiﬁcation of different mRNAs [2]. Protecting
genomic stability is important for normal cells in order to maintain
homeostasis, which will otherwise lead to carcinogenesis [3]. Cells
become genomically unstable under various conditions like DNA
damage by intrinsic [4] or extrinsic sources [5], chemotherapeutic
or radiation agents in cancerous as well as in normal bystander cells
[6e9], oncogene-induced replication stress [10,11], etc. However,
all these damages are ﬁxed by the DNA damage response and repair
network of signaling mechanisms [12], which is required for the
proper maintenance of genomic stability. Various types of DNA
damage are repaired by various types of DNA repair pathways. For
example, DNA double strand breaks (DSB)s [13] are repaired by
homologous recombination (HR) or non-homologous recombina-
tion (NHEJ), DNA crosslinks are repaired by Fanconi anemia (FA)logous recombination; NHEJ,
on repair; BER, base excision
; MIS, micro-instability syn-
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sion repair (NER) [15], base lesions are repaired by base excision
repair (BER) [16] and mis-incorporation of DNA bases during
replication is repaired by mismatch repair (MMR) [17], but some-
times these damages are bypassed by translesion synthesis (TLS)
pathway [18].
Most of the DNA damage response and repair proteins or genes
are activated by post-translational modiﬁcations like ubiquitina-
tion, phosphorylation, acetylation, etc or post transcriptionally by
miRNAs respectively. While single miRNA can target multiple
mRNAs, single mRNA can also be a target of multiple miRNAs.
Especially, miRNAs bind to the mRNAs and mediate their degra-
dation [19]. Degradation of mRNAs that are actively involved in
DNA repair changes cellular homeostasis. However, down-
regulation/degradation of the DNA repair miRNAs in cancer cells
potentially sensitizes them to chemotherapeutic agents, which
otherwise makes them chemoresistant. Similarly, cells that have
deﬁcient miRNA biosynthesis mechanism have defective cell cycle
regulation and DNA repair [20]. Studies have also shown that most
of the miRNAs are also altered, especially transcription of various
miRNAs are altered upon DNA damage [21]. Understanding the
basic mechanisms behind the miRNA-induced regulation of DNA
repair network in cancer cells will help us to design better thera-
peutic options. In this review we have focused on different types of
miRNAs that regulate DNA repair mechanisms in cancer cells and
how it will improve the therapeutic efﬁcacy of chemotherapeutic
agents.Ai Communications Co., Ltd. This is an open access article under the CC BY-NC-ND
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DSBs are the most lethal as well as the most susceptible DNA
damage for carcinogenesis. Approximately, a cell undergoes more
than ten DSB per day. Various exogenous agents like radiation,
chemotherapy and endogenous agents like oxidative metabolism,
V(D)J recombination are responsible for inducing DSB [22]. Owing
to its importance, DNA DSBs are repaired by two different mecha-
nisms, either HR or NHEJ. HR is an error free repair, which requires a
template DNA and occurs mostly in cells in the S/G2 phase of the
cell cycle where DNA is replicated; on the other hand, NHEJ is an
error prone repair, which simply rejoins the broken strands of DNA
and occurs mostly in G1 phase of the cell cycle, but also has limited
activity throughout the cell cycle [13].
2.1. MiRNA-induced regulation of DNA repair
Upon DNA damage, various repair members get activated and
act as sensors (H2AX), transducers (ATM/ATR), mediators (MDC1)
and effectors. Phosphorylation of H2AX at serine 139 is an impor-
tant process to recruit all DNA repair associated proteins and also
considered as a reliable marker for DNA DSB [23]. 3'UTR region of
H2AX is found to have a conserved region for the binding of miR-24
[24]. Expression of miR-24 was found to be high in terminally
differentiated cells and correlated well with decreased expression
of H2AX. This study reveals the basic mechanism behind the
reduced efﬁciency of DSB repair in terminally differentiated cells.
ATM (Ataxia-telangiectasia mutated) is an important serine/
threonine kinase that is required for the repair of DSB [25]. It was
found that miR-421 binds to 3'UTR region of ATM mRNA and fa-
cilitates its degradation [26]. Inhibition of ATM mRNA by miR-421
sensitized cancer cells to IR, which mimics the phenotype of AT
patients. Further analysis revealed that oncogene and transcription
factor N-Myc induces the expression of miR-421 in neuroblastoma.
This further conﬁrms the role of miRNA mediated suppression of
DNA repair and genomic instability, which ultimately leads to
carcinogenesis. Another important DSB transducer that works
similar to ATM is ATR, a serine/threonine kinase [27]. Recent
research found that ATR mRNA is a direct target of miR-185 and
regulates it post-transcriptionally. Further analysis showed that
irradiation of cancer cells downregulates the expression of miR-
185, which in turn upregulates ATR mRNA and results in active
repair of radiation induced DNA damage. However, downregulation
of ATR mRNA by transfection with pre miR-185 results in sensiti-
zation of cancer cells to irradiation [28].
Mediator of DNA damage checkpoint protein (MDC)1 is an
important member of DSB repair that is regulated by miRNAs [29].
Mice or human cells lacking MDC1 are sensitive to radiation
induced DNA damages. A recent study revealed that miR-22 binds
toMDC1mRNA and regulates it post-transcriptionally. Inhibition of
MDC1 during neoplasm associated replication stressmight result in
accumulation of DNA damage and genomic instability.
2.2. MiRNA-induced regulation of HR repair
BRCA1 is an important member of HR repair and is often
mutated in breast and ovarian cancer [30]. MiR-182 downregulates
BRCA1 mRNA expression by binding to its (BRCA1) 3'UTR in a non-
canonical manner. Inhibition of BRCA1 by ectopically over-
expressing miR-182 results in sensitization of breast cancer cells to
ionizing radiation and PARP1 inhibitor [31]. The results of this study
highlighted the potential impact of miRNAs in anticancer therapy.
Similarly, miR-1255b, miR-193b, and miR-148b were found to
regulate important HR proteins like BRCA1, BRCA2 and RAD51 [32].
Further analysis revealed that all the three miRNAs binds to BRCA1,Please cite this article in press as: V. Natarajan, Regulation of DNA repa
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the HR genes post-transcriptionally. Similarly, hypoxia induced
expression of miR-210 was found to regulate the expression of
RAD52, an important member of HR [33]. Rad51 mRNA was also
found to be regulated by miR-96 and increased expression of miR-
96 sensitized cancer cells to cisplatin and PARP inhibitors [34].
FA is another chromosomal instability disorder resulting from
mutations in 19 complimentary genes that are important for DNA
repair [35]. FA patients are often characterized by bone-marrow
failure and susceptibility to acute myelogenous leukemia, squa-
mous cell carcinoma of head and neck, hepatocellular carcinoma,
congenital abnormalities and infertility. FA proteins is required
mostly to ﬁx inter-strand cross links and also required during DNA
replication to maintain genomic stability [35].
Upon DNA damage, FANCD2 gets monoubiquitinated and lo-
calizes into the nucleus, where it forms a complex with BRCA1,
BRCA2 and RAD51, and facilitates homology mediated repair [36].
Recent research found that upregulation of miR-302 reduces the
monoubiquitination/foci formation of FANCD2 upon DNA damage
[37]. Cells with miR-302 overexpression and simultaneous treat-
ment with MMC showed increased chromosomal damage, a hall-
mark of deﬁcient FANCD2. Another member of FA pathway that has
been found to be regulated by miRNA is FANCG. Bioinformatic
analysis revealed thatmiR-23a binds to FANCGmRNA and regulates
it negatively [38]. It has been found that areca nut extracts (ANE) or
arecoline (ARE) induces DNA DSB by upregulating miR-23a, which
in turn downregulates FANCG expression. This observation is
important because ANE or ARE nut-chewing habits often results in
the development of oral cancer.
2.3. MiRNA-induced regulation of NHEJ repair
DNA-dependent protein kinase (DNA-PKcs) is an important
member of NHEJ playing an active role in V(D)J recombination,
which is required for maturation of B and T cells [27]. miR-101 was
found to bind to the 3'UTR region of DNA-PKcs and facilitate its
degradation. Interestingly, miR-101 has also been found to regulate
ATMmRNA in a similar way [39]. Downregulation of DNA-PKcs and
ATM mRNAs by miR-101 transfection and simultaneous treatment
with radiation sensitized the cancer cells by inhibiting DSB repair.
Similarly, 53BP1 which is necessary for NHEJ was also found to
be regulated by miR-34a. Inhibition of 53BP1 in glioblastoma cells
post-irradiation showed increased DNA damage associated with
mitotic catastrophe. Further analysis revealed that these cells do
not undergo G2/M arrest which usually happens after irradiation
[40]. Most chemotherapeutic agents that are now in use for cancer
therapy kill cancer cells by inducing DSB either directly or indi-
rectly. Therefore, it is important to study the role of miRNAs that
regulate DSB repair in detail, so as to improve therapeutic efﬁcacy
of cancer treatments.
3. MiRNA-induced regulation of nucleotide excision repair
NER is a specialized repair mechanism that is required for the
active repair of DNA adducts formed by UV and chemicals [41].
More than 25,000 bases per human genome per cell undergoes
DNA adducts induced damage every day. Various types of NER is
available for the repair of DNA adducts based on whether DNA
damage occurred in the transcribed region or in the un-transcribed
region. For example, GG-NER (global genome repair) takes place in
the total genomic DNA and TC-NER (transcription coupled repair) is
restricted to removing lesions preferentially from the transcribed
DNA strand of active genes.
ERCC3 otherwise called as XPB (xeroderma pigmentosum type
B) is a DNA helicase necessary for NER [42]. ERCC4 is anotherir by non-coding miRNAs, Non-coding RNA Research (2016), http://
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repair endonuclease XPF [43]. Functionally disabling mutations in
these two genes results in Xeroderma pigmentosum, Cockayne's
syndrome, and Trichothiodystrophy. It has been found that miR-
192 is able to bind and inhibit the mRNAs of ERCC3 and ERCC4 in
HepG2.2.15 cells that are stably transfected with HBV. It is inter-
esting to note that the control HepG2 cells not transfectedwith HBV
showed no reduction in ERCC3 and ERCC4 expression. This con-
ﬁrms that HBV induces the expression of miR-192, which in turn
represses NER by inhibiting ERCC3 and ERCC4. This study also
supports the fact that viral infection induced downregulation of
important DNA repair might be an important mechanism for viral
induced carcinogenesis [44]. Similarly, hypoxia induced expression
of miR-373 suppresses the expression of RAD23b mRNA, a protein
involved in NER [33].
4. MiRNA-induced regulation of mismatch repair
Six billion bases are replicated in each cell during replication.
Even though highly speciﬁc and reliable replication machinery
works to avoid any errors, there are always some errors that occur
during replication. Mis-match repair is speciﬁc for ﬁxing the errors
that take place during replication [45]. It mostly involves deletion,
insertion and mis-incorporation of bases. The nucleotide adenine
always base pairs with thymidine and guanine always base pairs
with cytosine. Mis-base paring is the most common error that
happens during replication [45]. Mutations in proteins that are
involved in MMR results in genomic instability syndrome called
microsatellite instability (MIS). Mutations in MMR are also associ-
ated with most of the cancers [46].
Similar to other types of DNA repair mechanisms, MSH2, MSH6
and MLH1, the important components of MMRmechanism are also
regulated by miRNAs. A study has shown that expression of miR-
155 signiﬁcantly downregulates the expression of MSH2, MSH6
and MLH1 mRNA [47]. Mutations in these genes are generally
associated with MIS or Lynch syndrome (LS), also known as he-
reditary nonpolyposis colorectal cancer (HNPCC). Analysis of MIS
tumor samples revealed at least two-fold increase in miR-155
expression compared to samples from adjacent controls. Howev-
er, association between miR-155 expression and the stages of tu-
mors are not signiﬁcant. This observation potentially conﬁrms the
role of miR-155 in MSI tumors by downregulating MMRmRNA. The
authors have concluded that MSI tumors with unknown MMR
defects may result from miR-155 overexpression.
Apart from MSI tumors, miR-155 induced regulation of MMR
mRNA has been observed in pancreatic cancer. A recent study has
shown that MLH1, an important member of MMR is downregulated
in the event of miR-155 overexpression [48]. Immuno-
histochemical analysis of pancreatic cancer samples showed
decreased expression of MLH1 compared to para-tumor samples of
pancreatic cancer.
miR-21 was also found to overexpress and regulate MSH2,
MSH6 mRNAs, especially in colorectal cancer [49]. In contrast to
other miRNAs discussed in this review, overexpression of miR-21 in
colorectal cancer reduces the therapeutic efﬁcacy of 5-FU. The au-
thors have described that the observed result is due to a defective
MMR mechanism. While overexpression of miR-21 in colorectal
cancer cells may not potentially sensitize the cells to chemothera-
peutic agents, it can be a good biomarker to evaluate 5-FU thera-
peutic efﬁcacy. It is important to note that different miRNAs
regulate the same mRNAs in different ways in different cancers. It
may be the result of a complex heterogeneity that happens in
cancer cells. Unraveling the basic mechanism behind this signaling
network is important for more focused and targeted cancer
therapy.Please cite this article in press as: V. Natarajan, Regulation of DNA repa
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Single base modiﬁcations like oxidation, methylation, uracil,
alkylation, and deamination results in improper formation of DNA
double helix. The BER mechanism speciﬁcally recognizes these
modiﬁcations and protects the DNA from genomic instability.
Mutations in genes that are involved in BER are often associated
with cancer. For example, somatic mutation of Pol b is found in 30%
of cancers and mutations in DNA glycosylase MYH increases the risk
of colon cancer [50].
Uracil, a demethylated form of thymidine nucleotide is mis-
incorporated in DNA and is regularly removed by BER mecha-
nism. Human nuclear uracil-DNA glycosylase (UNG2) is a member
of BER mechanism that is necessary to remove uracil from DNA.
Previous reports have shown that UNG2 proteins are down-
regulated during G2/M phase of cell cycle. Even though they found
that both mRNA and proteins of UNG2 is going down, they did not
uncover the mechanism behind this. A recent study revealed that
3'UTR region of UNG2 mRNAs is a direct target of miR-16, miR-34c,
andmiR-199a [51]. However, authors did conduct further studies to
sensitize cancer cells.
Human DNA polymerase b (DNA polymerase b, polb) is a protein
required for BER mechanism. A recent study found that miR-499
regulates DNA polymerase b in esophageal carcinoma cell lines
[52]. Further analysis found that miR-499 binds to the 3'UTR region
of DNA polymerase b mRNA and facilitates its degradation. The
authors observed that miR-499 overexpressed esophageal carci-
noma cell lines increased sensitivity towards cisplatin treatment
compared to esophageal carcinoma cell lines without miR-499
overexpression.
6. MiRNA-induced regulation of TLS
Most of the base damages or bulky adducts will be actively
repaired by BER or NER respectively. However, sometimes these
damages remain unrepaired and may stall replication fork pro-
gression. Stalling of replication fork will result in genomic insta-
bility or cell death. At the same time, cells have another repair
mechanism to overcome or bypass the damages by DNA damage
tolerance pathway or TLS pathway [53]. Basically, TLS pathway
members such as E3 ligase Rad18 and DNA polymerase h will
modify PCNA and facilitate the PCNA to bypass the damage during
replication, and allow the damage to be repaired later. Rad18 also
forms a complex with FA/BRCA repair proteins like FANCD2, BRCA1
and RAD51 and facilitates the camptothecin induced DSB repair
[36]. Among the different types of TLS proteins, Rad18 is an E3
ubiquitin ligase important for DNA damage tolerance pathway. Like
other important DNA repair proteins, we discussed before, Rad18 is
also found to be regulated by miRNAs. A Recent study shows that
the tumor suppressor miR-145 regulates Rad18 mRNA [54]. Over-
expression of miR-145 negatively correlates with Rad18 expression
in colorectal cancer patients, suggesting a direct link between
them. The results from this study also shows that RAD18 is over-
expressed in cancer cells that are resistant to 5-FU. This may be
because Rad18 might help 5-FU induced DNA damage to get
bypassed, thus protecting cancer cells from DNA damage induced
cell death. The chemoresistance induced by Rad18 makes it as a
potential therapeutic target. As expected, expression of miR-145 in
cancer cells and simultaneous treatment with 5-FU sensitized the
cancer cells by reversing chemoresistance. Apart from normal
regulation, DNA damage induced upregulation of miRNA-630 was
found to regulate Rad18 mRNA in HepG2 cells [55]. This is an
interesting observation of how DNA damage regulates DNA repair
proteins via miRNAs.
Apart from Rad18, DNA polymerase Rev1 involved in TLS wasir by non-coding miRNAs, Non-coding RNA Research (2016), http://
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increased the sensitivity of cancer cells to PARP inhibitors and
cisplatin treatment. Like Rad18, Rev1 also works with FANCD2 to
protect nascent DNA strands in response to replication stress [56].
While it is interesting to note that all DNA repair members are
interconnected and still exciting to note that they are differentially
regulated at different phase of cell cycle by speciﬁc miRNAs.7. Conclusion
DNA repair is an important signaling network critical for the
maintenance of genomic stability. The genes involved in DNA repair
are mostly regulated by post-transcriptional/translational modiﬁ-
cations, of which miRNA induced post-transcriptional regulation is
an important phenomenon leading to the downregulation of both
the mRNAs and protein. One of the main advantages of using
miRNAs for cancer therapy is that miRNAs have the ability to
sensitize cancer cells to chemotherapeutic agents by down-
regulating different DNA repair genes (Fig. 1). However, when one
type of DNA repair mechanism becomes defective, the cells adapt to
survive by activating another type of repair mechanism [57]. To
overcome the conundrum, future studies have to focus on targeting
miRNAs that can regulate more than one DNA repair gene. Another
important signaling pathway that functions closely in association
with the DNA repair pathway is the cell cycle pathway. Down-
regulation of DNA repair genes will induce DNA damage, and if the
cell cycle checkpoints are in place, it will allow more time for the
cells to repair [58]. For an effective cancer treatment, genes
involved in both DNA repair and cell cycle checkpoints have to be
downregulated simultaneously. Identifying miRNAs that can
potentially bind to mRNAs of both DNA repair and associated cell
cycle genes will be a beneﬁcial tool. Various types of novel thera-
peutic options are now available for cancer treatments, for example
stimulating apoptosis [59e61], use of bacterial toxins [62e64], DNA
repair inhibitors [65]. Combination of these approaches with
miRNA will also be an interesting method in the future.
In conclusion, cell speciﬁcity for miRNAs that regulate DNA
repair protein coding genes has to be validated further. Down-
regulation of DNA repair genes under normal conditions would
result in increased genomic instability, leading to carcinogenesis.
Identifying the basic mechanism of miRNA-induced regulation in
normal versus cancer cells will provide useful information to in-
crease the therapeutic efﬁcacy of cancer treatment using miRNAs.Please cite this article in press as: V. Natarajan, Regulation of DNA repa
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